Ajinomoto CELLiST Korea has announced the launch of CELLiSTTM AAV Production Supplement 1, a newly developed medium supplement designed to significantly enhance viral vector productivity in gene therapy manufacturing.
The supplement was developed through collaboration between Ajinomoto Co. and its US-based consolidated subsidiary, Forge Biologics, a leading CDMO specialising in adeno-associated virus (AAV) development and manufacturing.
Demonstration studies confirmed that CELLiSTTM AAV Production Supplement 1 improves the productivity of viral vector manufacturing by one to two times compared to conventional culture methods.
The results of this joint research were presented at the Japan Society of Gene and Cell Therapy (JSGCT) in July 2025.
The advancement addresses one of the most critical challenges in the fast-growing gene therapy field: improving productivity while reducing manufacturing costs.
With the global gene therapy market projected to expand from $7bn in 2022 to $46bn by 2030, efficient production solutions such as CELLiSTTM AAV Production Supplement 1 are essential to meet rising demand for both prevalent and rare disease therapies.
For more than three decades, Ajinomoto CELLiST Korea has been committed to innovation in the biopharmaceutical field, offering high-performance CELLiSTTM culture media optimised for CHO and HEK293 cell lines.
By combining the Ajinomoto Group’s advanced formulation optimisation technologies with Forge Biologics’ large-scale AAV manufacturing expertise, the launch of CELLiSTTM AAV Production Supplement 1 represents a significant step forward in applying AminoScience to accelerate the future of gene therapy manufacturing.
Ajinomoto CELLiST Korea will leverage CELLiSTTM AAV Production Supplement 1 to support customers mainly in Asia seeking to enhance their viral vector production efficiency.
"We are excited to introduce CELLiSTTM AAV Production Supplement 1 to our customers," said President Sugiyama of Ajinomoto CELLiST Korea.
"Building on the Ajinomoto Group’s strong R&D foundation, our goal is to help gene therapy developers achieve higher productivity, better scalability and more reliable outcomes in their manufacturing processes."
Ajinomoto CELLiST Korea remains committed to advancing the AminoScience-based solutions that drive innovation in biopharmaceutical manufacturing, from monoclonal antibodies to next-generation cell and gene therapies.